Cedric Pobel, MD, discusses how the results of the PEACE-1 trial support the use of radiotherapy plus standard of care and abiraterone in low-volume metastatic castration-sensitive prostate cancer.

In a powerful talk with Mathew Knowles and Courtney Bugler, CEO of Zero Prostate Cancer, we highlight the urgent need for awareness among Black men at risk.

The health secretary said he is 'particularly sympathetic' to the arguments being made for the need to proactively offer ...

Rashes are a common side effect of some prostate cancer treatments. Rarely, they may be caused by cancer cells.

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which ...

Several biomarker tests have been available for over a decade, with extensive research backing their effectiveness. Yet, many urologists remain unaware of their full potential to streamline practice ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

The report forecasts global market growth from $116.1 billion in 2024 to $168 billion by 2029 at a CAGR of 7.7%. Highlighting advances in immunotherapy, CAR-T cell therapy, and biomarker-based ...

The National Comprehensive Cancer Network celebrated its 30th anniversary with a series of presentations on cancer care ...

King Charles was taken to hospital on Thursday for ‘a short period of observation’ after experiencing side effects from his ...

Neoplastic Agents Market Report 2025" has been added to ResearchAndMarkets.com's offering.This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, ...

AbbVie (NYSE: ABBV) today announced that new data from its early oncology research will be showcased across multiple presentations at the upcoming American Association of Cancer Research (AACR) Annual ...